Search Results 291-300 of 21342 for anti-TNF drugs

1. Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease - Mayo Clinic

   Combination Therapy: Anti-TNF Combination Therapy Group (approximately 40-50% of the group): on anti-TNF therapy as described above along with either 15mg ...

2. Rubella Virus Vaccine, Live (Subcutaneous Route) Before Using - Mayo Clinic

   Adalimumab; Anifrolumab-fnia; Ansuvimab-zykl ... Etanercept; Etrasimod; Everolimus; Fidanacogene ... drugs may be the best treatment for you. If both ...

3. Dolutegravir (Oral Route) Description and Brand Names - Mayo Clinic

   ... anti-HIV medicines in the past or to replace their current anti-HIV medicines. HIV is the virus that causes acquired immune deficiency syndrome (AIDS) ...

4. New study finds rheumatology prescribing, spending linked to pharmaceutical payments - Mayo Clinic News Network

   Ali Duarte Garcia, M.D.. "Before the 2000s most of the treatments for rheumatic diseases consisted of non-steroidal anti-inflammatory medications, or NSAIDS, ...

5. Fluconazole (Oral Route) Description and Brand Names - Mayo Clinic

   Fluconazole is also used to prevent candidiasis in patients having bone marrow transplants who receive cancer or radiation treatment. This medicine is available ...

6. Senescent cells: Promising anti-aging targets for health span extension and the treatment of osteoporosis - Mayo Clinic

   Kirkland and Farr and collaborators reported the first senolytic drugs — agents that selectively eliminate senescent cells — in a 2015 article in Aging Cell. Dr ...

7. Cellular Responses to DNA Damage Induced by Topoisomerase Poisons - Anticancer Drug Action Laboratory - Mayo Clinic Research

   This enzyme is also the target of the anti-cancer drugs irinotecan, topotecan, MM398, PLX038 and CBX-12, along with a growing number of antibody-drug conjugates ...

8. Certolizumab (Subcutaneous Route) Before Using - Mayo Clinic

   Drugs and Supplements · Certolizumab (Subcutaneous ... Adalimumab; Adenovirus Vaccine Type 4, Live ... Certain medicines should not be used at or around ...

9. Adrian T. Ting, Ph.D. - Mayo Clinic Faculty Profiles

   This has posed a challenge to its potential use in anti-tumor therapy. Furthermore, TNF -mediated cytotoxicity presumably evolved as an antimicrobial mechanism, ...

10. Antihistamine/Decongestant Combination (Oral Route) Description and Brand Names - Mayo Clinic

    In November 2000, the Food and Drug Administration (FDA) issued a public health warning regarding phenylpropanolamine (PPA) due to the risk of hemorrhagic ...